4/A: Incyte Corp: Executive Earns Performance Shares

Incyte Corporation reports that Pablo J. Cagnoni, President, Global Head of R&D, has earned performance shares based on achievement of specified criteria.

Summary

• Pablo J. Cagnoni, President, Global Head of R&D at Incyte Corporation, has been awarded 31,517 shares of common stock.
• These shares are performance shares earned upon the achievement of performance criteria determined on May 6, 2026.
• The earned shares are subject to vesting on the third anniversary of the July 14, 2023 grant date, contingent on continued service.
• The performance criteria included specified development, revenue, and market-based goals, such as relative total shareholder returns compared to the Nasdaq Biotechnology Index.
• This filing is an amendment to a previous Form 4 filed on April 17, 2026, to reflect the Compensation Committee's determination on May 6, 2026, which superseded an earlier determination on April 15, 2026.
• Following this certification, Mr. Cagnoni beneficially owns 266,317 shares of common stock, including shares issuable from previously reported restricted stock units and unvested performance shares.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it confirms the achievement of performance goals by a key executive, but it does not represent new strategic information or significant financial results.

Positives

• Achievement of performance criteria by a key executive indicates progress towards company goals.
• The earning of performance shares suggests positive performance in development, revenue, or market-based metrics.
• The total beneficial ownership of 266,317 shares indicates significant alignment of executive interest with the company.

Risks

• Vesting of earned shares is subject to continued service with the Issuer, meaning departure before the vesting date would result in forfeiture.
• The number of shares ultimately received can range from 0% to 150% of the awarded performance shares, depending on performance over the three-year period.
• The performance goals are tied to development, revenue, and market-based metrics, which are subject to inherent business and market risks.

Future Outlook

The future outlook for the earned performance shares is contingent on the reporting person's continued service and the achievement of specified performance goals over the three-year period, with vesting occurring on the third anniversary of the grant date.

Management Comments

• The earned shares will vest on the third anniversary of the July 14, 2023 grant date, subject to the Reporting Person's continued service with the Issuer.
• Each performance share represents the right to receive one or more shares of common stock based on, and subject to, specified development, revenue and market-based (relative total shareholder returns compared to the Nasdaq Biotechnology Index) performance goals determined by the Issuer's Compensation Committee in January 2023 as set forth in the Performance Share Award Agreement.
• The number of shares of common stock that the Reporting Person is entitled to receive over the three-year performance period ranges from 0% to 150% of the number of performance shares awarded.

Industry Context

StockSavvy.ai notes that the granting and earning of performance shares tied to development, revenue, and market-based metrics is a common practice in the biotechnology and pharmaceutical industry to incentivize executive performance and align their interests with shareholder value.

Corporate Governance

Stakeholder Impact

• Shareholders: The earning of performance shares by a key executive can be viewed positively as it aligns executive incentives with company performance and shareholder value.
• Employees: The success in achieving performance metrics may indirectly benefit employees through overall company growth and stability.
• Management: Confirms the executive's role and compensation structure, reinforcing their commitment to the company's objectives.

Next Steps

• Vesting of earned performance shares on the third anniversary of the July 14, 2023 grant date, subject to continued service.
• Continued monitoring of performance against development, revenue, and market-based goals over the three-year performance period.

Key Dates

Keywords

Incyte Corporation, INCY, Form 4, Statement of Changes in Beneficial Ownership, Performance Shares, Stock Options, Executive Compensation, R&D, Securities Exchange Act, SEC Filing